Breaking News
March 22, 2018 - New ocular inserts allow patient’s cornea to absorb more antibiotics
March 22, 2018 - FDA Alert: NeuroBlate Probe by Monteris Medical: Letter to Health Care Providers, Class I Recall
March 22, 2018 - Morning Break: Booze Study Brouhaha; Stem Cells for MS; Big Debt Problem
March 22, 2018 - New wearable tech from Western may hold big benefits for people with Parkinson’s
March 22, 2018 - Immune cells can repopulate in the retina after elimination, mice study shows
March 22, 2018 - Research provides better understanding of how cancerous cells behave in low oxygen
March 22, 2018 - Menopausal hormone therapy taken soon after menopause may benefit the brain
March 22, 2018 - Booze Boosts Your Heart Rate
March 22, 2018 - Skeptical Cardiologist: Classifying Heart Failure
March 22, 2018 - Instead of nagging your spouse to lose weight, try going on a diet yourself
March 22, 2018 - Neem Biotech to share findings on cystic fibrosis biofilm disruption at ECFS Basic Science Conference
March 22, 2018 - Study uncovers new genetic cause of posterior polymorphous corneal dystrophy
March 22, 2018 - ENDO: Big Breakfast May Help in Diabetics
March 22, 2018 - I’m not overweight, so why do I need to eat healthy foods?
March 22, 2018 - UCLA-led study suggests unexpected reason for reduction in cardiovascular health disparities
March 22, 2018 - Study suggests detailed neuropsychological assessment for brief cardiac arrest survivors
March 22, 2018 - Anticoagulant drugs found safe to use in patients undergoing surgery for irregular heartbeat
March 22, 2018 - SP Industries appoints Brian Larkin as new President and CEO
March 22, 2018 - GTx Announced New Data Demonstrating Enobosarm’s Potential to Treat Stress Urinary Incontinence
March 22, 2018 - Higher Risk of Brain Deficits in Older Alcoholics
March 22, 2018 - Top US health official resigns in conflict of interest
March 22, 2018 - Study shows benefits of hair loss drug in improving cognitive function and vascular health
March 22, 2018 - Researchers explain link between 2 key Alzheimer’s proteins
March 22, 2018 - Patients on replacement therapy with thyroid hormone may have more comorbidities
March 22, 2018 - Higher online patient ratings linked to urologists who saw fewer Medicare patients
March 22, 2018 - FDA Approves Ilumya (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis
March 22, 2018 - Beer Raises Heart Rate; KardiaBand Hyperkalemia Test; CHD Clinics
March 22, 2018 - A retinal implant that is more effective against blindness
March 22, 2018 - New system based on artificial intelligence provides reliable detection of breast cancer
March 22, 2018 - Research offers new understanding about cause of Parkinson’s disease
March 22, 2018 - HORIBA’s Microsemi CRP analyzer improves quality of care in emergency pediatric units, study shows
March 22, 2018 - Neuroscientists move closer to developing tools for deciphering brain function
March 22, 2018 - New test methods with less fear
March 22, 2018 - Range of Vaginal Dryness Products Can Help Postmenopausal Women: Study
March 22, 2018 - Higher Dose Tx Deemed Safe in Pulmonary TB
March 22, 2018 - Discovery of new ALS gene points to cytoskeleton as potential target for drug development
March 22, 2018 - Diet soda associated with higher odds of diabetic retinopathy
March 22, 2018 - LSD reduces ‘sense of self’
March 22, 2018 - Vitamin D deficiency linked to metabolic syndrome in postmenopausal women
March 22, 2018 - Changes in the intestines may be responsible for reversal of diabetes after bariatric surgery
March 22, 2018 - iPads and Cancer; Clot Retrieval and Stroke: It’s PodMed Double T!
March 22, 2018 - Premature births linked to changes in mother’s bacteria
March 22, 2018 - Brain SPECT scans predict treatment outcomes in patients with depression
March 21, 2018 - Researchers succeed in integrating artificial organelles into cells of living organism
March 21, 2018 - Researchers discover ‘missing mutation’ in severe infant epilepsy
March 21, 2018 - Researchers develop statistics-based computational scheme to zoom in on brain function
March 21, 2018 - Verge joins Genomics England’s Discovery Forum industry partnership
March 21, 2018 - Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial
March 21, 2018 - Congenital Cardiac Cath Tx Often Strays from Guidelines
March 21, 2018 - Marked increase in cardiovascular risk factors in women after preeclampsia
March 21, 2018 - New app may help predict, track manic and depressive episodes in bipolar patients
March 21, 2018 - Discovery of genes could lead to development of novel therapies for EBV-related cancers
March 21, 2018 - High-fat, high-cholesterol diet depletes ranks of artery-protecting immune cells
March 21, 2018 - Research misconduct allegations shadow likely CDC appointee
March 21, 2018 - Most Breast Ca Patients Fail to Get Genetic Counseling
March 21, 2018 - Lopsided ear function can lead to lopsided brain development
March 21, 2018 - Acupuncture helps manage menopausal symptoms, review finds
March 21, 2018 - Motor skill training may contribute to reading skills in obese children
March 21, 2018 - Poor dental health may be related to increased diabetes risk
March 21, 2018 - Chronic opioid users at increased risk of complications after spinal fusion surgery
March 21, 2018 - Study uncovers potential therapeutic target against large family of parasites
March 21, 2018 - NSAID use linked to increased risk of atrial fibrillation
March 21, 2018 - Scientists develop brain “stethoscope” that can detect silent seizures
March 21, 2018 - New method predicts effects of global warming on disease
March 21, 2018 - Insurance Company Hurdles Burden Doctors, May Harm Patients
March 21, 2018 - Renal Transplant from HCV-Positive Donors Feasible
March 21, 2018 - Myelodysplastic syndrome: MedlinePlus Medical Encyclopedia
March 21, 2018 - Research reveals brain mechanism involved in language learning
March 21, 2018 - Many parents still hesitate to try early peanut introduction, survey finds
March 21, 2018 - Audiologist urges tinnitus sufferers facing ‘revolving door healthcare’ to seek support
March 21, 2018 - Study reveals impact of prostate cancer on wives and partners of sufferers
March 21, 2018 - ‘Almost a Miracle Drug’: What We Heard This Week
March 21, 2018 - Study shows NIH spent >$100 billion on basic science for new medicines
March 21, 2018 - Columbia researchers identify nerve cells that drive fruit fly’s escape behavior
March 21, 2018 - Sartorius Stedim Biotech selected by ABL Europe to supply single-use process technologies
March 21, 2018 - Increase in coffee consumption may help battle against colon cancer
March 21, 2018 - Hydrogel may accelerate healing of diabetic ulcers
March 21, 2018 - Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
March 21, 2018 - DePuy Synthes introduces ACTIS Total Hip System for improving initial implant stability
March 21, 2018 - ‘Oh, It Was Nothing’
FDA Approves Apalutamide (Erleada) to Help Curb a Tough-to-Treat Prostate Cancer

FDA Approves Apalutamide (Erleada) to Help Curb a Tough-to-Treat Prostate Cancer

image_pdfDownload PDFimage_print

WEDNESDAY, Feb. 14, 2018 — A new drug that can stall the progression of a particularly hard-to-treat form of prostate cancer has been approved for use by U.S. health officials.

In a recent study, the drug called Erleada (apalutamide) has shown breakthrough effectiveness in keeping prostate cancer from spreading for two years in men whose disease had not yet traveled to other parts of their body.

After the drug was granted Priority Review by the U.S. Food and Drug Administration, the agency announced Wednesday that it had approved Erleada “for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy.”

A second, already approved drug, Xtandi (enzalutamide), has also shown similar effectiveness against these types of prostate cancer cases.

Dr. Matthew Smith was primary researcher of the Erleada trial that helped lead to the new approval. His team published its results Feb. 8 in the New England Journal of Medicine.

Smith explained that men newly diagnosed with prostate cancer that hasn’t spread are first treated with androgen-deprivation therapy — a medication that robs the tumor of the testosterone that helps fuel its growth.

This strategy “always works, and [then] it almost always stops working,” said Smith, who directs the genitourinary malignancies program at Massachusetts General Hospital in Boston.

“And when it stops working, that’s what we call castration-resistant prostate cancer,” he explained.

Until now, there have been no approved treatments for prostate cancer at that stage, Smith said. The men are simply put under observation until their cancer migrates, at which point treatment resumes.

Tens of thousands of men in the United States are estimated to be in this situation and they have a very poor prognosis, particularly if their levels of prostate-specific antigen (PSA) are rapidly rising, Smith said. PSA is a protein produced by the prostate gland; a sudden elevation of PSA levels has been linked to increased prostate cancer risk.

“There’s an unmet need there,” Smith said. “Their expected survival is similar to that of men with newly diagnosed prostate cancer that has already spread to bone.”

Both Erleada and Xtandi battle prostate cancer by binding to the androgen receptor on tumor cells, blocking its activation by testosterone and other male hormones, explained Dr. Oliver Sartor, medical director of the Tulane Cancer Center in New Orleans. He co-wrote a commentary accompanying the apalutamide trial.

“Both the drugs are incredibly similar to one another,” Sartor said. “If you look at the chemical structure, they’re extremely close to one another. Mechanistically, they operate the same way.”

In the Erleada trial, Smith’s group tested the pill against a placebo.

The result: Erleada extended progression-free survival by about two years over a placebo, researchers found — 40.5 months versus 16.2 months. That means patients continued to live their lives without the disease progressing.

Men taking Erleada had a 72 percent lower risk of invasive cancer or death, based on results from more than 1,200 patients at 322 sites in 26 countries, the study found.

“It was a very big effect,” Smith said.

The FDA said that, in a first for cancer drugs, it based its approval of Erleada not on overall survival results, but on how long patients survived without their cancer spreading.

For his part, Smith said he expects Erleada to become the standard of care for men with this form of prostate cancer.

But other experts think Xtandi could steal the new drug’s thunder.

Dr. Alexander Kutikov, chief of urologic oncology with Fox Chase Cancer Center in Philadelphia, noted that Xtandi demonstrated similar results in studies, and it’s already in use as a prostate cancer therapy.

“I suspect barriers to its use, at least initially, will be much lower than to that of apalutamide [Erleada],” he said.

Sartor agreed. “I think [Erleada] will become a standard of care. I hesitate to think it will be the standard of care,” he said.

And he noted that both drugs come with significant side effects — most commonly rash and increased risk of fracture — and men not suffering any symptoms might not want to take the risk of drug-related adverse events.

For example, rash occurred in almost 24 percent of men taking Erleada versus 5.5 percent in the placebo group. And fractures occurred in close to 12 percent of Erleada users, versus 6.5 percent in the placebo group. However, only about 10 percent of men taking the cancer drug dropped out due to side effects, compared with 7 percent and 8 percent of the placebo groups.

The Erleada trial was paid for by Johnson & Johnson.

More information

For more on prostate cancer, visit the U.S. National Cancer Institute.

© 2018 HealthDay. All rights reserved.

Posted: February 2018

Tagged with:

About author

Related Articles